Literature DB >> 7549229

Angiotensin II enhances responses to endothelin-1 in bovine bronchial smooth muscle.

J E Nally1, R A Clayton, M J Wakelam, N C Thomson, J C McGrath.   

Abstract

Angiotensin II and endothelin-1 are putative mediators in asthma. In this study we have examined the effect of angiotensin II on endothelin-1-induced contractions in bovine bronchi and the receptor types involved in the response to these agonists. Angiotensin II alone is very low in potency, producing only small contractions. In the presence of angiotensin II 10(-7) or 3 x 10(-7) M, contractions evoked by endothelin-1 were markedly enhanced. The AII1-receptor antagonist, losartan, abolished this enhancement suggesting that angiotensin II exerts this effect via an AII1-receptor. The contraction evoked by endothelin-1 is mediated via an EtA-receptor subtype since the EtA-receptor antagonist FR139317 attenuated the response. This is offset by an inhibitory EtB-type receptor, resulting in a larger contraction when these receptors are desensitized. Indeed, the EtB-receptor agonist sarafotoxin S6c reversed methacholine-evoked tone in a concentration-dependent manner. In conclusion, angiotensin II potentiates contractions evoked by endothelin-1 in bovine bronchi. This may be a mechanism by which angiotensin II--which has little activity in bronchi--may evoke substantial changes in airway tone. Angiotensin II evokes this potentiation via AII1-receptors, whilst endothelin-1 evokes contraction via EtA-receptors, an action which is offset by an inhibitory effect of EtB-receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7549229     DOI: 10.1006/pulp.1994.1048

Source DB:  PubMed          Journal:  Pulm Pharmacol        ISSN: 0952-0600


  6 in total

Review 1.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

2.  Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man.

Authors:  R R Wenzel; J Rüthemann; H Bruck; R F Schäfers; M C Michel; T Philipp
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

3.  Angiotensin II induces hyperresponsiveness of bronchial smooth muscle via an activation of p42/44 ERK in rats.

Authors:  Hiroyasu Sakai; Yuko Nishizawa; Ayako Nishimura; Yoshihiko Chiba; Kumiko Goto; Motohiko Hanazaki; Miwa Misawa
Journal:  Pflugers Arch       Date:  2010-05-22       Impact factor: 3.657

4.  Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma.

Authors:  Shigeharu Myou; Masaki Fujimura; Yumie Kamio; Toshiyuki Kita; Kazuyoshi Watanabe; Yoshihisa Ishiura; Takuma Hashimoto; Shinji Nakao
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

5.  All-Trans Retinoic Acid Exerts Neuroprotective Effects in Amyotrophic Lateral Sclerosis-Like Tg (SOD1*G93A)1Gur Mice.

Authors:  Yu Zhu; Yue Liu; Fang Yang; Wenzhi Chen; Jianxian Jiang; Pei He; Shishi Jiang; Menhua Li; Renshi Xu
Journal:  Mol Neurobiol       Date:  2020-06-17       Impact factor: 5.682

Review 6.  Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review.

Authors:  Oskar Puk; Aleksandra Nowacka; Klaudia Smulewicz; Katarzyna Mocna; Wiktor Bursiewicz; Natalia Kęsy; Justyna Kwiecień; Michał Wiciński
Journal:  Biomed Pharmacother       Date:  2021-12-25       Impact factor: 6.529

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.